Pharmabcine Inc.

Other

Yonsei University

Genemedicine Co., Ltd.

Industry-university Cooperation Foundation Hanyang University

Korea Research Institute of Bioscience and Biotechnology

The Green Cross Corporation

Mogam Biotechnology Research Institute

St Pharm Co., Ltd.

Theragenetex Co., Ltd.

Industry-academic Cooperation Foundation

Chae-Ok Yun

Young-Guen Kwon

Joo-Hang Kim

Sung-Woo Kim

Jin-San Yoo

Do-Yun Kim

Sang-Seok Koh

Hyeon-Mi Yoo

Hyun-Sook Jang

Geun-Bae Rha

Dong-Sup Lee

Weon-Sup Lee

Sang-Ryeol Shim

Mi-Hee Park

Jeong-Eun Kang

Dong-Heon Lee

Bo-Jeong Pyun

Young-Woo Park

Jae-Won Jeon

Nahm-Ju Kim

Kwi-Hwa Kim

Too-Hyon Cho

Sam-Sook Sul

Semi Kim

Joon-Chul Lee

Young Ho Kim

Jin Soo Kim

Yoon Ah Kang

Kyuhyun Lee

Young Il Yeom

Hee Gu Lee

Seongtae Yun

Eui-Cheol Jo

Kyung-Sook Chung

Daekyung Koh

Eun Young Song

Moon Hee Kim

Young-Joo Kim

Kyeong-Eun Jung

Hyun Chul Shin

Seon-Young Kim

Kyung Bin Song

Misun Won

Hong-Kyu Lee

Jeong-Ki Min

Mihee Hwang

Ho Kyung Chun

Young-Myeong Kim

Jai-Myung Yang

Joo Hang Kim

Sun-Jung Cho

Shin-Jung Choi

Joon Chul Lee

Se-mi Kim

The present invention relates to a novel gene delivery system and recombinant adenovirus comprising the decorin-encoding sequence to enhance transduction efficiency of transgenes, a pharmaceutical anti-tumor composition comprising the recombinant adenovirus, a pharmaceutical composition having improved tissue penetration potency and a pharmaceutical composition for treating a disease or disorder associated with accumulation of excess extracellular matrix.

Decorin gene delivery system and cancer treatment

The present invention relates to a recombinant adenovirus capable of regulating angiogenesis, which comprises (a) an adenoviral UR (inverted terminal repeat) nucleotide sequence; and (b) a transcription regulatory sequence for a VEGF-A (vascular endothelial growth factor-A) gene comprising (i) a nucleotide sequence encoding a DNA binding domain comprising a zinc finger domain to bind to a site in a VEGF-A promoter sequence as set forth in nucleotides 1-2362 of SEQ ID NO:1, and (ii) a transcription activation domain or a transcription inhibitory domain linked to the nucleotide sequence encoding the DNA binding domain; and a pharmaceutical composition comprising the recombinant adenovirus.

Recombinant adenoviruses capable of regulating angiogenesis

A novel gene delivery system and recombinant adenovirus includes a decorin-encoding sequence to enhance transduction efficiency of transgenes. A pharmaceutical anti-tumor composition includes the recombinant adenovirus, as well as a pharmaceutical composition having improved tissue penetration potency and a pharmaceutical composition for treating a disease or disorder associated with accumulation of excess extracellular matrix.

The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.

Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof

Disclosed is a recombinant adenovirus with a protein containing a VSV-G epitope derived from vesicular stomatitis virus (VSV). Also, the present invention discloses a pharmaceutical composition comprising such a recombinant adenovirus and a pharmaceutically acceptable carrier. Further, the present invention discloses a recombinant plasmid capable of expressing the recombinant adenovirus and a host cell transformed with the recombinant adenovirus.

Recombinant adenovirus with enhanced therapeutic effect and pharmaceutical composition comprising said recombinant adenovirus

Provided are tumor-specific promoters, oncolytic virus vectors and a pharmaceutical composition comprising the virus vector. The virus vector comprising the novel tumor-specific promoter shows excellent oncolytic effects on tumor cells, and thus it is useful for treating a cancer.

Tumor specific promoter and oncolytic virus vector comprising the same

Provided are a composition for diagnosing cancer or screening an anticancer drug comprising an FLJ25416 gene or an antibody directed to a protein expressed from the FLJ25416 gene, a composition for treating cancer comprising an inhibitor of the gene or an inhibitor of the protein expressed from the gene and a pharmaceutically acceptable carrier, and a kit for diagnosing cancer comprising at least one of the FLJ25416 gene and the protein expressed from the FLJ25416 gene. The FLJ25416 gene is expressed at high level in specific cancer cells, and induces an increase in proliferation rate of normal cells. The expression of the gene is suppressed, which results in an inhibitory effect on cancer cell growth. Thus, the FLJ25416 gene can be used as a target gene for diagnosis or treatment of cancer.

Use of FLJ25416 gene

Disclosed is a method for coexpressing IL-12 (interleukin-12) and IL-23 (interleukin-23), which comprises the steps of: (a) preparing vectors comprising monocistronic expression constructs of each of nucleotide sequences encoding the p35 subunit, the p40 subunit and the p19 subunit, or preparing a vector comprising a polycistronic expression construct of nucleotide sequences encoding the p35 subunit, the p40 subunit and the p19 subunit; (b) transforming the expression constructs into a host cell; and (c) culturing the transformed host cell to obtain IL-12 and IL-23, a vector for coexpressing IL-12 and IL-23, and a pharmaceutical anti-tumor composition comprising the vectors.

Methods for effectively coexpressing IL-12 and IL-23

The present invention relates to a method for stimulating angiogenesis using by DKK2 and composition comprising the same. The DKK2 protein of the present invention showed stimulating activities of tube formation on HUVEC, promoting activity of the sprouting of arterial circle tissues and promoting activity of vascular development in the embryo of mouse. Therefore, it can be used as the therapeutics or functional health food for treating and preventing ischemic disease.

Method for stimulating angiogenesis using DKK2 and composition comprising the same

The present invention relates to a transcriptional regulatory sequence with enhanced tumor-specificity and strength and a recombinant vector comprising the transcriptional regulatory sequence. More particularly, the present invention relates to a transcriptional regulatory sequence comprising a human telomere reverse transcriptase (hTERT) promoter linked to a nucleotide sequence that comprises one or more c-Myc binding sites and/or one or more Sp1 binding sites, and a recombinant vector comprising a certain gene that is operably linked to the above transcriptional regulatory sequence.

Modified tert promoter with enhanced tumor-specificity and strength and recombinant vector comprising the same

Growing community of inventors

Seoul, South Korea

Chae-Ok Yun